🧬 BioMed Pulse · 2026-09-17 02:02 UTC

BIOMED PULSE

September 17, 2026 | Daily Briefing on Longevity, Viruses & New Cures

⚡ TL;DR

The Bundibugyo virus Ebola outbreak in the Democratic Republic of the Congo has now become the largest Ebola outbreak ever recorded in that country, with 61 health zones across six provinces affected as of September 10, 2026. The overall mood is grave on outbreak news but quietly productive on longevity science and drug approvals.

🦠 OUTBREAKS & VIRUSES

EBOLA (BUNDIBUGYO VIRUS) - DRC AND UGANDA: RECORD-BREAKING OUTBREAK

• As of September 10, 2026, a cumulative total of confirmed cases spans 61 health zones across six DRC provinces: Bas-Uele, Haut-Uele, Ituri, North Kivu, South Kivu, and Tshopo, making this the largest Ebola outbreak ever reported in DRC. ^[1]
• One new health zone, Kayna in North Kivu, was added since the August 28 update, reflecting continued geographic spread driven by sustained community transmission. ^[1]
• Cross-border transmission to Uganda remains active, a pattern WHO first flagged when Bundibugyo ebolavirus was laboratory-confirmed in both countries in mid-May 2026. ^[2]
• The outbreak originated in Mongbwalu Health Zone, Ituri Province, after a high-mortality illness of unknown origin was reported on May 5, 2026, with the Institut national de recherche biomedicale confirming Bundibugyo virus on May 14. ^[3]
• By July 1, the outbreak had already recorded 1,460 confirmed cases and 452 deaths in DRC; by July 15 those figures had climbed to 2,124 confirmed cases and 828 deaths, a roughly 45% increase in cases in just two weeks. ^{[4] [5]}
• WHO characterized the outbreak in August as "expanding faster than any previous Ebola outbreak," driven by sustained transmission in urban and semi-urban settings. ^[6]
• CDC activated enhanced Ebola airport screening at Washington Dulles International on May 21 and expanded screening to Atlanta's Hartsfield-Jackson airport on May 23, 2026. ^{[7] [8]}

ANDES HANTAVIRUS - M/V HONDIUS CRUISE SHIP, MULTI-COUNTRY

• WHO's fifth Disease Outbreak News posting (July 2, 2026) on the Andes hantavirus (ANDV) cluster confirmed ongoing case investigation following initial notification on May 2, 2026 of severe acute respiratory illness aboard the M/V Hondius cruise ship carrying 147 passengers and crew. ^[9]
• By the third WHO DON (May 13, 2026), two additional confirmed cases had been reported since the May 8 update, with laboratory confirmation specifically identifying Andes hantavirus as the causative pathogen. ^[10]
• CDC issued multiple transcript briefings through June 24, 2026 continuing to update the hantavirus response and noting the risk to the American public remains extremely low.

MEASLES - BANGLADESH

• WHO notified on April 23, 2026 of a nationwide surge in measles affecting 58 of 64 districts across all eight divisions of Bangladesh, with 19,161 suspected cases and 2,897 laboratory-confirmed cases reported as of that date.

NIPAH VIRUS - INDIA

• WHO confirmed one laboratory-confirmed Nipah virus (NiV) infection on June 25, 2026 in an adult male in Kozhikode district, Kerala State, India, who developed neurological symptoms beginning May 30, 2026 and was hospitalized June 10.

YELLOW FEVER - GLOBAL

• WHO's June 24, 2026 Disease Outbreak News reported that from January 1 to May 26, 2026, six countries reported a cumulative 79 human yellow fever infections in the Americas and Africa, following elevated transmission activity that carried over from 2025.

ANIMAL RABIES - UNITED STATES

• CDC issued a statement on September 10, 2026 flagging a notable increase in recent animal rabies activity and associated human exposures across the United States, urging prompt post-exposure prophylaxis evaluation.

CYCLOSPORA - TACO BELL LETTUCE, UNITED STATES

• CDC identified shredded iceberg lettuce served at Taco Bell locations in five states as the source of cyclosporiasis infections affecting 1,644 people as of July 17, 2026, with the outbreak expanding to four additional states by July 24.

WEST NILE VIRUS - UNITED STATES

• CDC warned on July 1, 2026 of an early West Nile season with record case counts ahead of the July 4th holiday weekend, urging mosquito bite prevention measures.

DRUG-RESISTANT BACTERIA - UNITED STATES

• A CDC report released September 23, 2025 found a dramatic increase in dangerous drug-resistant bacteria in the United States, reinforcing the ongoing antimicrobial resistance threat in healthcare settings.

CONGENITAL SYPHILIS - UNITED STATES

• CDC data released September 24, 2025 showed U.S. cases of newborn syphilis increased for the 12th consecutive year in 2024, signaling persistent gaps in prenatal STI screening and treatment.

🧬 LONGEVITY & AGING

SIRT1, GUT MICROBIOTA, AND COGNITIVE AGING

• A review in Medical Gas Research (Maiese K., August 2026) links oxidative stress, the longevity-associated protein SIRT1, and gut microbiota dysbiosis to a "neurocardiac" mechanism underlying cognitive decline in aging, suggesting the gut-brain axis as a therapeutic target.

CELLULAR SENESCENCE IN OSTEOARTHRITIS

• Researchers published in Bioactive Materials (An et al., July 2026) show that combining antioxidant and epigenetic therapies can break the "self-perpetuating senescence cycle" in osteoarthritis cartilage, pointing to senolytic-plus-epigenetic combination strategies for joint aging.

SENESCENCE-ASSOCIATED SECRETORY PHENOTYPE (SASP) MAPPING IN SKIN CELLS

• A Methods in Molecular Biology paper (Koutsoukos et al.) describes multiplex assay characterization of SASP in both primary and iPSC-derived skin cells, providing a reproducible toolkit for measuring the inflammatory signals secreted by senescent cells across aging models.

IONIZING RADIATION AND HAIR FOLLICLE SENESCENCE

• A Genes and Disease study (Jia et al., published March 2026) shows ionizing radiation drives senescence in dermal papilla cells by suppressing the FOXM1-KIF20A molecular pathway, a mechanism relevant to radiation-exposed patients and space medicine research.

MOLECULAR HYDROGEN AS RADIOPROTECTANT

• A Medical Gas Research paper (Ichikawa et al., September 12, 2026) proposes molecular hydrogen (H2) as a potential guardian against environmental radiation damage by neutralizing hydroxyl radicals, the primary reactive oxygen species generated by radiation exposure.

BONE REPAIR IN AGING: mRNA NANOPARTICLE APPROACH

• A Bioactive Materials study (Cheng et al., August 2026) describes a dual-targeting mRNA lipid nanoparticle that restores ABCA1-dependent cholesterol homeostasis in aged bone tissue, demonstrating improved repair of age-related bone defects in preclinical models.

EGFR LOSS AND IMPAIRED FRACTURE HEALING IN AGED MICE

• Hu et al. in Bioactive Materials (August 2026) find that loss of epidermal growth factor receptor (EGFR) activity in skeletal stem and progenitor cells is directly associated with the well-known impairment of fracture healing seen in aged animals, identifying EGFR as a potential therapeutic target.

YOUNG PLASMA EXOSOMES FOR ALZHEIMER'S DISEASE

• Chen et al. in Bioactive Materials (August 2026) report that engineered exosomes derived from young plasma can reduce amyloid pathology and neuroinflammation in Alzheimer's disease models, advancing the "young blood" concept toward a cell-free, scalable therapeutic format.

EXOSOMES IN BRAIN DISEASE

• A broad Bioactive Materials review (Cheng et al., August 2026) maps mechanisms by which exosomes contribute to or protect against neurodegeneration, stroke, and traumatic brain injury, highlighting their dual roles as biomarkers and drug delivery vehicles in brain aging.

DEPRESCRIBING IN OLDER ADULTS

• Two commentaries in Lancet Healthy Longevity (Hwang et al. and Van der Linden) argue that clinical trials testing reduction or cessation of medications in older patients need a "rationale-first" framework to select the right trial design, warning that inappropriate deprescribing trial designs could produce misleading results.

HIP FRACTURE SURGERY ANAESTHESIA IN OLDER PATIENTS

• A multicentre randomized clinical trial published in Lancet Healthy Longevity (Kowark et al.) from Germany compared spinal versus general anaesthesia for hip fracture surgery in older patients, addressing a long-standing clinical controversy with direct implications for peri-operative mortality in the elderly.

INTERVERTEBRAL DISC REGENERATION

• Jiang et al. in Bioactive Materials (September 2026) review precision biomaterial strategies for intervertebral disc regeneration, including niche reprogramming and structural reconstruction approaches targeting the age-related degeneration responsible for chronic back pain in older populations.

OSTEOARTHRITIS EXTRACELLULAR VESICLES

• Yang et al. in Bioactive Materials (September 2026) characterize how extracellular vesicles in osteoarthritis joints can act as either disease drivers or repair promoters depending on cellular context, with implications for designing vesicle-based therapies for aging joints.

QUERCETIN NANOCOMPOSITE FOR OSTEOPOROTIC BONE

• A Bioactive Materials study (Yin et al., August 2026) describes a microenvironment-responsive nanocomposite hydrogel incorporating quercetin-derived carbon dots and M2 macrophage-derived migrasomes that promoted bone regeneration in osteoporotic defect models, targeting the inflammatory and oxidative environment characteristic of aged bone.

💊 NEW CURES & APPROVALS

ISEMBYLD (APITEGROMAB-MSTN) - SCHOLAR ROCK INC: ORIGINAL APPROVAL

• Scholar Rock Inc received original FDA approval (BLA761463) for Isembyld, active ingredient apitegromab-mstn, a myostatin inhibitor that blocks the activin receptor ligand myostatin; the drug targets muscle-wasting conditions and represents the first approved agent in its mechanistic class.

IMDELLTRA (TARLATAMAB-DLLE) - AMGEN INC: SUPPLEMENTAL APPROVAL

• Amgen Inc received a supplemental FDA approval (BLA761344) for Imdelltra (tarlatamab-dlle), a bispecific T-cell engager (BiTE) targeting DLL3 on small cell lung cancer cells, expanding its approved indications beyond the initial approval.

EPINEPHRINE - ZYDUS PHARMACEUTICALS: ORIGINAL APPROVAL

• Zydus Pharmaceuticals received an original FDA approval (ANDA219832) for an epinephrine formulation, adding a new generic manufacturer to the emergency anaphylaxis treatment supply.

CARBIDOPA AND LEVODOPA - SUN PHARMACEUTICAL INDUSTRIES: SUPPLEMENTAL APPROVAL

• Sun Pharmaceutical Industries received a supplemental approval (ANDA078536) for carbidopa/levodopa, the cornerstone combination therapy for Parkinson's disease, relevant to the aging population where Parkinson's prevalence rises sharply after age 60.

COLISTIMETHATE SODIUM - SAGENT PHARMACEUTICALS: SUPPLEMENTAL APPROVAL

• Sagent Pharmaceuticals received a supplemental FDA approval (ANDA201365) for colistimethate sodium, a last-resort antibiotic used against extensively drug-resistant Gram-negative bacteria, notable given CDC's recent report of rising drug-resistant bacterial infections.

PRIMAQUINE PHOSPHATE - UNICHEM AND ALVOGEN: SUPPLEMENTAL APPROVALS

• Both Unichem (ANDA204476) and Alvogen (ANDA203924) received supplemental FDA approvals for primaquine phosphate, the key antirelapse agent for Plasmodium vivax and P. ovale malaria, supporting anti-malarial drug supply particularly relevant after WHO certified Timor-Leste malaria-free in July 2025.

🧪 CLINICAL TRIALS

RSV AND HMPV BIVALENT VACCINE IN ADULTS 60-PLUS: PHASE 2B PROOF OF CONCEPT

• ClinicalTrials.gov study NCT07810010 (updated September 16, 2026) is a Phase 2b observer-blind, randomized, placebo-controlled trial enrolling approximately 8,000 adults aged 60 years and older to assess clinical efficacy, safety, and immunogenicity of a single intramuscular injection of a bivalent RSV plus human metapneumovirus (HMPV) protein vaccine candidate, targeting the two leading causes of severe respiratory illness in older adults.

PACRITINIB FOR MYELODYSPLASTIC SYNDROMES AND MDS/MPN: PHASE 2

• NCT06303193 (updated September 16, 2026) tests pacritinib, a kinase inhibitor of CSF1R, IRAK1, JAK2, and FLT3, in adults and pediatric participants aged 12 and older with myelodysplastic syndromes or myelodysplastic/myeloproliferative neoplasms, conditions that increase in prevalence with age and can progress to acute myeloid leukemia.

NEOANTIGEN TCR T-CELL THERAPY FOR BLOOD CANCERS: PHASE 1/2

• NCT06904066 (updated September 16, 2026) tests autologous T cells transduced with retroviral vectors expressing participant-specific neoantigen T-cell receptors in patients with hematologic malignancies, including those harboring TP53 or RAS mutations, targeting the individualized cancer immune surveillance approach.

BASE-EDITED STEM CELL GENE THERAPY FOR WHIM SYNDROME

• NCT07775313 (updated September 16, 2026) evaluates base-edited hematopoietic stem and progenitor cell gene therapy for WHIM syndrome (warts, hypogammaglobulinemia, infections, and myelokathexis), caused by CXCR4 mutations, representing a first-in-human precision gene editing approach for this rare immune disorder.

BARICITINIB FOR JOB SYNDROME WITH LUPUS-LIKE DISEASE

• NCT07262983 (updated September 16, 2026) evaluates the safety and tolerability of baricitinib, a JAK1/JAK2 inhibitor, in patients with autosomal dominant hyper-IgE syndrome (Job syndrome) presenting with lupus-like disease or atopic dermatitis, exploring JAK inhibition for a rare genetic immunological condition.

N-ACETYL-D-MANNOSAMINE (MANNAC) FOR PODOCYTE KIDNEY DISEASES: PHASE 2

• NCT06664814 (updated September 16, 2026) is an open-label Phase 2 study of N-Acetyl-D-Mannosamine in subjects with podocyte diseases including focal segmental glomerulosclerosis, minimal change disease, and membranous nephropathy, conditions that drive protein leakage and progressive kidney failure in aging patients.

HIGH-VELOCITY RESISTANCE TRAINING VERSUS OTAGO EXERCISE FOR FALL RISK IN ELDERLY

• NCT07204808 (updated September 16, 2026) compares high-velocity resistance training against the established Otago Exercise Programme on fall risk reduction in elderly participants, directly addressing one of the leading causes of injury-related death in adults over age 65.

TRAUMATIC INTRACRANIAL HEMORRHAGE OUTCOMES IN ADULTS OVER 65: OBSERVATIONAL

• NCT07822724 (updated September 16, 2026) is an observational study describing clinical and radiological characteristics of traumatic intracranial hemorrhage in adults aged 65 and older, noting that even low-energy falls such as ground-level trips can cause fatal brain bleeding in this age group.

GROWTH HORMONE AND THE AGING IMMUNE SYSTEM

• NCT00663611 (updated September 16, 2026) investigates whether growth hormone administration can reverse the age-associated decline in immune function in elderly individuals, studying its role in the increased incidence of infection, autoimmune disorders, and cancer seen in aging.

📢 PUBLIC HEALTH

CDC BIOSURVEILLANCE MILESTONE

• CDC's Traveler-Based Genomic Surveillance program surpassed one million voluntary air travel participants as of January 30, 2026, strengthening the agency's capacity to detect emerging pathogens at ports of entry.

CDC IMMUNIZATION SCHEDULE UPDATE: COVID-19 AND CHICKENPOX

• CDC updated both adult and child immunization schedules on October 6, 2025 to apply individual-based decision-making for COVID-19 vaccines and to allow standalone varicella (chickenpox) vaccination for toddlers, replacing the previous combined MMRV preference.

LISTERIA OUTBREAK LINKED TO PREPARED MEALS: ONGOING

• CDC urged consumers as recently as October 30, 2025 to check refrigerators and freezers for recalled prepared meal products; 3 additional illnesses and 1 additional death were reported in a September 26, 2025 update expanding the outbreak to more prepared food categories.

SALMONELLA OUTBREAK LINKED TO MORINGA PRODUCTS: EXTENSIVELY DRUG-RESISTANT

• Three people were hospitalized in a February 2026 outbreak of extensively drug-resistant Salmonella linked to moringa powder capsules, with CDC issuing a broader alert in May 2026 noting a growing number of illnesses and outbreaks across multiple moringa leaf product types.

SALMONELLA OUTBREAK LINKED TO JALAPEÑOS: AUGUST 2026

• CDC posted a food safety alert on August 5, 2026 warning of a multistate Salmonella outbreak linked to jalapeños, adding to a pattern of produce-linked outbreaks throughout 2025-2026.

ALFALFA SPROUT OUTBREAK: DUAL E. COLI AND SALMONELLA

• CDC warned on August 21, 2026 of a multistate outbreak linked to recalled alfalfa sprout products causing illness from both E. coli and Salmonella simultaneously, an unusual dual-pathogen outbreak.

KINDERGARTEN VACCINATION RATES: SLIGHT DECLINE NOTED

• CDC data released August 17, 2026 showed kindergarten vaccination rates remain broadly high but recorded a slight 0.1% decline in coverage, a signal to monitor given the ongoing national measles situation.

U.S. WITHDRAWAL FROM WHO COMPLETED

• The United States formally completed its withdrawal from the World Health Organization on January 22, 2026, with WHO stating on January 24 that the decision "makes both the United States and the world less safe."

This briefing is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider for personal health decisions.

📎 Sources

1. Ebola disease caused by Bundibugyo virus - Democratic Republic… — WHO Disease Outbreak News
2. Ebola disease caused by Bundibugyo virus – Democratic Republic… — WHO Disease Outbreak News
3. Ebola disease caused by Bundibugyo virus, Democratic Republic … — WHO Disease Outbreak News
4. Ebola disease caused by Bundibugyo virus, Democratic Republic … — WHO Disease Outbreak News
5. Ebola disease caused by Bundibugyo virus, Democratic Republic … — WHO Disease Outbreak News
6. Ebola disease caused by Bundibugyo virus - Democratic Republic… — WHO Disease Outbreak News
7. Enhanced Ebola Airport Screening Begins at Washington-Dulles I… — CDC Newsroom
8. Enhanced Ebola Airport Screening Expands to Atlanta — CDC Newsroom
9. Hantavirus outbreak linked to cruise ship travel, Multi-locations — WHO Disease Outbreak News
10. Hantavirus cluster linked to cruise ship travel, Multi-country — WHO Disease Outbreak News

Curated from official sources — WHO/CDC/ECDC/openFDA/ClinicalTrials.gov/Europe PMC. Informational only — not medical advice.
Serial 20260917-02-v78 · 2026-09-17 02:02 UTC · pulse.uzylab.com